Our lab has conducted a comprehensive, multi-platform analysis of prostate cancer patient samples collected during progression of the disease from the time of initial referral, at prostatectomy, on biochemical recurrence and at the appearance and expansion of metastases (Hong et al., 2015 Nat Commun 6:6605) . This study has allowed us to identify some of the drivers of metastases in prostate cancer. One candidate driver that was found to be mutated in 50% of metastatic cancers, but only 5% of localised tumors prior to metastasis, was the tumor suppressor TP53. In order to characterise the functional contribution of TP53 mutations we have produced stably transfected LNCaP cell lines that contain a number of common TP53 mutations and are subjecting them to routine cell culture assays relevant to cancer progression. Our preliminary data indicates that TP53 mutations can dampen the induction of senescence.